Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
AbbVie acquires Mavupharma, developer of small molecules that activate STING
by Ryan Cross
July 19, 2019
| A version of this story appeared in
Volume 97, Issue 29
AbbVie has acquired Mavupharma, a small Seattle-based biotech company, for an undisclosed sum. Mavupharma’s lead candidate is an inhibitor of an enzyme called ENPP1. Inhibiting that enzyme increases the activity of another protein known as STING, which itself enhances the innate immune system. The goal is to boost the efficacy of existing cancer immunotherapies. Several drug companies are trying to activate STING directly, which often requires injecting a drug into tumors. Mavupharma’s small molecule has the advantage of potentially being a pill.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter